

Vanessa Vi Innao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1242828/publications.pdf>

Version: 2024-02-01

56
papers

1,264
citations

471061

17
h-index

433756

31
g-index

56
all docs

56
docs citations

56
times ranked

2228
citing authors

#	ARTICLE	IF	CITATIONS
1	Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies. <i>Cancer Investigation</i> , 2017, 35, 1-22.	0.6	164
2	Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. <i>Mediators of Inflammation</i> , 2017, 2017, 1-24.	1.4	99
3	The Cancer Stem Cell Hypothesis: A Guide to Potential Molecular Targets. <i>Cancer Investigation</i> , 2014, 32, 470-495.	0.6	77
4	Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. , 2018, 182, 176-192.		76
5	New orally active proteasome inhibitors in multiple myeloma. <i>Leukemia Research</i> , 2014, 38, 1-9.	0.4	66
6	Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies. <i>Annals of Hematology</i> , 2020, 99, 1953-1965.	0.8	54
7	Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. <i>European Journal of Haematology</i> , 2013, 90, 441-468.	1.1	46
8	Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw. <i>Annals of Hematology</i> , 2018, 97, 1259-1269.	0.8	44
9	Reduced β 2-microglobulin plasma levels in multiple myeloma patients are associated with more advanced stage of disease. <i>British Journal of Haematology</i> , 2013, 160, 709-710.	1.2	37
10	Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 62, 49-63.	0.6	34
11	The metabolomic signature of hematologic malignancies. <i>Leukemia Research</i> , 2016, 49, 22-35.	0.4	29
12	Nanobodies and Cancer: Current Status and New Perspectives. <i>Cancer Investigation</i> , 2018, 36, 221-237.	0.6	28
13	Therapeutic potential of antagomiRs in haematological and oncological neoplasms. <i>European Journal of Cancer Care</i> , 2020, 29, e13208.	0.7	23
14	Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2822.	1.8	21
15	Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw. <i>Tohoku Journal of Experimental Medicine</i> , 2019, 248, 27-29.	0.5	21
16	Vaccination of multiple myeloma: Current strategies and future prospects. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 339-354.	2.0	20
17	Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network. <i>Journal of Clinical Medicine</i> , 2019, 8, 877.	1.0	20
18	Corneal Structural Changes in Nonneoplastic and Neoplastic Monoclonal Gammopathies. , 2016, 57, 2657.		18

#	ARTICLE	IF	CITATIONS
19	Telomerase and telomere biology in hematological diseases: A new therapeutic target. <i>Leukemia Research</i> , 2017, 56, 60-74.	0.4	18
20	Formaldehyde Exposure and Acute Myeloid Leukemia: A Review of the Literature. <i>Medicina (Lithuania)</i> , 2019, 55, 638.	0.8	18
21	Immune checkpoint inhibitors in multiple myeloma: A review of the literature. <i>Pathology Research and Practice</i> , 2020, 216, 153114.	1.0	17
22	Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age. <i>Blood</i> , 2013, 122, 539-539.	0.6	17
23	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020, 105, 1074-1080.	1.7	16
24	New Frontiers about the Role of Human Microbiota in Immunotherapy: The Immune Checkpoint Inhibitors and CAR T-Cell Therapy Era. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8902.	1.8	16
25	Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	15
26	The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention. <i>European Journal of Internal Medicine</i> , 2018, 53, 12-20.	1.0	14
27	Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 689-698.	0.2	14
28	Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma. <i>Cells</i> , 2021, 10, 448.	1.8	14
29	Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma. <i>Cells</i> , 2021, 10, 439.	1.8	14
30	New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges. <i>Cancers</i> , 2021, 13, 1981.	1.7	14
31	Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials. <i>Expert Review of Hematology</i> , 2019, 12, 665-684.	1.0	13
32	The ST2/Interleukin-33 Axis in Hematologic Malignancies: The IL-33 Paradox. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5226.	1.8	13
33	Relationship between mitofusin 2 and cancer. <i>Advances in Protein Chemistry and Structural Biology</i> , 2019, 116, 209-236.	1.0	13
34	Post-chemotherapy cognitive impairment in hematological patients: current understanding of chemobrain in hematology. <i>Expert Review of Hematology</i> , 2020, 13, 393-404.	1.0	13
35	Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma. <i>Antioxidants</i> , 2019, 8, 55.	2.2	12
36	Myeloma cells induce the accumulation of activated CD94 ^{low} NK cells by cell-to-cell contacts involving CD56 molecules. <i>Blood Advances</i> , 2020, 4, 2297-2307.	2.5	11

#	ARTICLE	IF	CITATIONS
37	Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs. <i>Current Oncology</i> , 2021, 28, 159-183.	0.9	11
38	Vaccination strategies in lymphoproliferative disorders: Failures and successes. <i>Leukemia Research</i> , 2015, 39, 1006-1019.	0.4	10
39	Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review). <i>Oncology Reports</i> , 2020, 43, 1729-1736.	1.2	10
40	Standardisation of minimal residual disease in multiple myeloma. <i>European Journal of Cancer Care</i> , 2017, 26, e12732.	0.7	9
41	Radioprotective Agents and Enhancers Factors. Preventive and Therapeutic Strategies for Oxidative Induced Radiotherapy Damages in Hematological Malignancies. <i>Antioxidants</i> , 2020, 9, 1116.	2.2	9
42	SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma. <i>Clinical Biochemistry</i> , 2021, 93, 42-49.	0.8	9
43	Extramedullary Plasmacytoma of the Maxilla Simulating a Maxillary Radicular Cyst. <i>Journal of Craniofacial Surgery</i> , 2016, 27, e296-e297.	0.3	8
44	Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib. <i>In Vivo</i> , 2019, 33, 1593-1598.	0.6	8
45	Changes in Serum Interleukin-8 and sRAGE Levels in Multiple Myeloma Patients. <i>Anticancer Research</i> , 2020, 40, 1443-1449.	0.5	8
46	Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. <i>Cancers</i> , 2019, 11, 1735.	1.7	7
47	Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey. <i>Frontiers in Oncology</i> , 2021, 11, 624405.	1.3	7
48	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021, 11, 73.	2.8	7
49	Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4922.	1.8	7
50	Quantitative polymerase Chain reaction profiling of microRNAs in peripheral lymph-monocytes from MGUS subjects. <i>Pathology Research and Practice</i> , 2021, 218, 153317.	1.0	5
51	A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant. <i>Annals of Hematology</i> , 2020, 99, 331-341.	0.8	4
52	Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma. <i>Archives of Medical Science</i> , 2021, 18, 696-703.	0.4	3
53	Disappearance of Acquired Hemophilia A after Complete Remission in a Multiple Myeloma Patient. <i>Turkish Journal of Haematology</i> , 2017, 34, 184-185.	0.2	3
54	Mitochondria-Targeted Antioxidant SkQ1 for Gammopathy-Related Corneal Damage. <i>American Journal of Therapeutics</i> , 2020, 27, e309-e310.	0.5	0

#	ARTICLE	IF	CITATIONS
55	A rare spinal localization of gray zone lymphoma without mediastinal involvement: a case report and review of literature. <i>Gazzetta Medica Italiana Archivio Per Le Scienze Mediche</i> , 2019, 178, .	0.0	0
56	Preliminary Results of a Prospective Observational Study to Assess the Prevalence of Gaucher Disease in an Adult Population Affected By MGUS. <i>Blood</i> , 2019, 134, 4868-4868.	0.6	0